SOLO PARA USO EN INVESTIGACIÓN. Datos de referencia para investigación de laboratorio. No es consejo médico; no apto para consumo humano.
Peptijournal

Comparar compuestos

Seleccione hasta 3 compuestos para comparar protocolos, mecanismos, criterios de valoración y hallazgos de seguridad en paralelo.

PopularesRetatrutide vs TirzepatideSemaglutide vs TirzepatideSemaglutide vs RetatrutideBPC-157 vs TB-500BPC-157 vs GHK-CuSermorelin vs Tesamorelin
IGF-1 LR3
Mismo objetivo
Incluir al imprimir

Solo afecta la página impresa o el PDF. El aviso de uso exclusivo en investigación siempre se imprime.

Protocolo01
IGF-1 LR3

Hormona del crecimiento

Viales · 1 mg

01Protocol

Viales
1 mg
Datos de dosis
Referencia de laboratorio; no indicado

02Quick calculator

Extraer (100u)

—

Concentración

—

mg/mL

03Mechanism of action

Long R3 IGF-I has a 13-amino-acid N-terminal extension and replaces Glu3 of the IGF-I sequence with Arg. Reduced IGF-binding-protein interaction helps explain enhanced potency in certain cell assays; this does not establish prolonged activity in humans.

04Study endpoints

  • Recombinant LR3 IGF-1 produced in yeast showed bioactivity comparable to standard IGF-1.
  • Anti-doping analysis of a black-market product identified His-tagged Long R3 IGF-I, a form whose effects in humans have not been described.

05Safety & regulatory findings

  • Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
  • Listed as prohibited in sport by the World Anti-Doping Agency.
  • No human clinical trials of LR3 are cited; black-market products may contain unexpected variants.

06Citations

3 referencias · ver